FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| STATEMENT | OF CHANGES | S IN BENEFICIAL | OWNERSHIP |
|-----------|------------|-----------------|-----------|
| | | | |

| OMB APPROVAL | | | | | | | | | | |
|---------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | | |
| Estimated average b | ourden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person* <u>Ticho Barry</u> | | | | 2. Issuer Name and Ticker or Trading Symbol Stoke Therapeutics, Inc. [STOK] | | | | | | | (Che | elationship o ck all applic Director | able) | Perso | on(s) to Issu 10% Ov Other (s | /ner | |
|--|--|------------|-----------------|--|---|--|------------------------------|---|------|---|--|---|--|--|-------------------------------------|-------|--|
| (Last) (First) (Middle) C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE | | | | 3. Date of Earliest Transaction (Month/Day/Year) 03/15/2022 | | | | | | | | below) | | | below) | poony | |
| | | | | 1. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | Line | dividual or Joint/Group Filing (Check Applicable) K Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date | | | . Transacti | Day/Year) Execution Date, if any (Month/Day/Year) Transaction Code (Instr. 3) Disposed Of (D) (Instr. 3) | | | ed (A) or str. 3, 4 and 5 | 5. Amount of Securities Form Beneficially (D) of | | Form: | Direct Indirect str. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | | | | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | ivative Conversion Date Execution Date, Tractivity or Exercise (Month/Day/Year) if any | | , Trans Code | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | | | |
| | | | | Code | v | (A) | (D) | Date Exercisable | | cpiration ate | Title | Amount or Number of Shares | | (Instr. 4) | JII(3) | | |
| Employee Stock Option (Right to Buy) | \$20.34 | 03/15/2022 | | A | | 107,400 | | (1) | 03 | 8/14/2032 | Common Stock | 107,400 | \$0.00 | 107,40 | 0 | D | |

Explanation of Responses:

1. The option vests as to 1/48th of the total shares on April 15, 2022 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

Remarks:

/s/ Stephen Tulipano, Attorneyin-Fact

03/17/2022

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{*} If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).